Key Details
The proposals address different stages of the pharmaceutical chain, from approval to manufacture an antimicrobial through to the storage and distribution of finished medicines. These are four draft changes across two sets of rules, rather than one amendment already in force.
Draft Change | What It Would Do |
|---|---|
Antimicrobial approval | Bring antimicrobials within the “new drug” definition under the New Drugs and Clinical Trials Rules, 2019, requiring Central Licensing Authority permission before a manufacturer applies for a state manufacturing licence |
Good Storage and Distribution Practices | Incorporate standards for procurement, storage, transport, distribution and records into the Drugs Rules, 1945 |
Bulk-drug wholesale licensing | Create a separate licence for wholesalers selling active or inactive bulk substances, distinct from the licence covering finished formulations |
Product-specific manufacturing rules | Continue specified exemptions under revised Schedule M for medicinal gases, empty gelatin capsules and disinfectant fluids |
Antimicrobials Would Face Central Scrutiny Before State Licensing
Under the proposed amendment to the New Drugs and Clinical Trials Rules, 2019, manufacturers would first seek permission from the Central Licensing Authority and then apply to the relevant State Licensing Authority for a manufacturing licence. The Ministry says the change responds to concerns that some antimicrobial products have received manufacturing licences without adequate scrutiny, including relevant bioavailability, bioequivalence or stability studies.
The proposal connects medicine quality with antimicrobial resistance (AMR): an antimicrobial that does not work as intended can compromise treatment and contribute to resistance. It concerns the scrutiny of products before licensing; it does not, on its own, address prescribing practices or sales without prescriptions.
Storage and Distribution Standards Would Follow Medicines Beyond the Factory
The proposed Good Storage and Distribution Practices (GSDP) amendment would bring existing regulatory guidance into the Drugs Rules, 1945. It covers how pharmaceutical products are procured, stored, transported, distributed and documented after manufacture or import.
The aim is to preserve product quality through the distribution chain and give central and state drug regulators a clearer basis for inspection. Appropriate conditions and reliable records matter where medicines pass between manufacturers, importers, wholesalers, distributors and stockists before reaching patients.
Bulk-Drug Sales Would Receive a Dedicated Licence
Currently, a common wholesale licence covers both bulk drugs — the active or inactive substances used to make medicines — and finished formulations. The proposed separate licence would identify the categories of bulk substances a wholesaler handles, including those subject to controls under the Narcotic Drugs and Psychotropic Substances Act. Sales would take place under the personal supervision of a competent person.
Existing licensees would have a transition period. The requirement would apply when their current retention period expires or 12 months after the amendment is finally published, whichever is later.
Schedule M Requirements Would Be Tailored to Specific Products
A separate draft would continue certain exemptions available before the 2023 revision of Schedule M, which sets good manufacturing practice requirements. The Ministry says some revised provisions may be unsuitable for the manufacturing processes of medicinal gases, empty gelatin capsules and disinfectant fluids. Licensing authorities would be able to make product-specific decisions while applying relevant quality standards.
Policy Relevance
The proposals combine closer scrutiny of higher-risk decisions with more specific rules for different products and businesses. Central review of antimicrobials would alter the approval sequence for manufacturers; GSDP and separate bulk-drug licensing would give regulators more defined information and standards for following products through the supply chain.
The consultation should test whether regulators have clear, workable criteria for antimicrobial assessments, consistent inspection of storage and transport conditions, and identification of bulk-drug wholesalers. It should also establish precisely which Schedule M requirements warrant exemption for the three specified product categories. Patient-safety and AMR benefits remain intended outcomes, to be assessed after any final rules are implemented.
Relevant Question for Policy Stakeholders: How can central and state drug regulators coordinate product approvals, wholesale licensing and distribution inspections so that weaknesses at one stage do not undermine medicine quality at the next?
Follow the Full Press Releases Here: Antimicrobial Oversight Proposal | Bulk-Drug Wholesale Licensing Proposal | Health Ministry’s Further Drug-Rule Proposals